MS1819 Plus PERT Aids Digestion in People With Severe EPI, Trial Indicates

MS1819 Plus PERT Aids Digestion in People With Severe EPI, Trial Indicates

294243

MS1819 Plus PERT Aids Digestion in People With Severe EPI, Trial Indicates

Combining AzurRx BioPharma‘s investigational therapy MS1819 with standard pancreatic enzyme replacement therapy (PERT) can improve fat absorption in cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI), interim data from a Phase 2 clinical trial indicate. “The overarching goal of our MS1819 program is to provide a safe and effective therapy to control EPI, a debilitating gastrointestinal condition common to patients with cystic fibrosis that can result in numerous, life-altering complications, including malnutrition,” James Pennington, MD, chief…

You must be logged in to read/download the full post.